{"schema_version":"secwatch.filing_event.v1","accession":"0001055726-26-000019","form_type":"8-K","ticker":"INO","cik":"0001055726","company_name":"INOVIO PHARMACEUTICALS, INC.","filed_at":"2026-05-13T20:07:44+00:00","discovered_at":"2026-05-13T20:09:00.298595+00:00","generated_at":"2026-05-13T20:10:52.309778+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Inovio Q1 net loss $19.7M ($0.28/shr); cash runway into Q1 2027 beyond Oct PDUFA","bullets":["Net loss $19.7M, flat YoY; diluted EPS ($0.28) vs ($0.51) due to fewer shares.","Revenue not reported (pre-revenue biotech); R&D spend $14.1M (-12% YoY), G&A $7.9M (-12%).","Cash & equivalents $37.7M at Mar 31, plus $16M from April offering; expects ops into Q1 2027.","FDA reviewing INO-3107 BLA under accelerated approval; PDUFA date Oct 30, 2026.","Collaboration with Akeso to test INO-5412 + cadonilimab in GBM in Dana-Farber INSIGhT trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001055726-26-000019","json":"https://secwatch.observer/filing/0001055726-26-000019.json","markdown":"https://secwatch.observer/filing/0001055726-26-000019.md","text":"https://secwatch.observer/filing/0001055726-26-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/0001055726-26-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-20260513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T20:10:52.309778+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}